Introducing peanut in infancy Prevents peanut allergy into adolescence
On May 28, 2024, a National Institute of Allergy and Infectious Diseases (NIAID) funded study reported that feeding…
-
-
Oral immunotherapy induced remission of peanut allergy in some young children
On Jan. 20, 2022, a clinical trial funded by the National Institutes of Health (NIH) found that giving…
-
Jubilant HollisterStier broke ground for $285 Million Spokane facility expansion
On Nov. 17, 2021, Jubilant HollisterStier broke ground for our $285 million Spokane facility expansion. This expansion is…
-
Two-year PALFORZIA data showed on-going safety and efficacy and continued immunomodulation in patients with peanut allergy
On Jun. 8, 2020, Aimmune Therapeutics announced two-year data that suggested long-term efficacy of daily treatment with PALFORZIA…
-
Aimmune announced first U.S. patients treated with PALFORZIA, the first treatment for peanut allergy
On Mar. 16, 2020, Aimmune Therapeutics announced that the first patients in the U.S. were being treated with…
-
Jubilant Organosys acquired Hollister-Stier
On Apr. 25, 2007, Jubilant Organosys, Ltd. announced it had acquired Spokane-based Hollister-Stier for $122.5 million. The plant…
